trending Market Intelligence /marketintelligence/en/news-insights/trending/d_k5jq7fo_9pi4bbpdktrq2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Iovance Biotherapeutics raising $219.3M to fund cancer therapies

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Iovance Biotherapeutics raising $219.3M to fund cancer therapies

Iovance Biotherapeutics Inc. said it priced a public offering of 22 million common shares at $9.97 per share.

The San Carlos, Calif.-based company expects gross proceeds of $219.3 million from the offering, which is expected to close Oct. 16.

The developer of cancer therapies also granted underwriters an option to buy up to an additional 3.3 million shares.

Iovance plans to use the proceeds from the offering to commercialize its lead experimental drug and potential melanoma treatment lifileucel, as well as fund the studies for cancer therapy LN-145 and for other general corporate purposes.

Jefferies LLC is acting as sole book-running manager for the offering.